Study on BGB-16673 for Patients with B-Cell Blood Cancers
Sponsor: BeiGene
ClinicalTrials ID:NCT05006716
This clinical trial is testing a new drug, BGB-16673, to find the best dose and evaluate its safety in patients with B-cell blood cancers. The study is divided into two parts: the first part focuses on finding the right dose, and the second part expands to more patients to further assess the treatment's effects.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The study aims to determine the best dose of a new drug, BGB-16673, for treating B-cell blood cancers. It consists of two main phases. The first phase involves testing different doses to find the safest and most effective one. The second phase involves expanding the study to more patients to better understand how the drug works and its safety profile.
Eligibility Criteria
Exclusion Criteria
- Have had another type of cancer within the last 2 years, unless it was a minor cancer that was successfully treated.
- Need ongoing treatment for another type of cancer.
- Require regular use of high-dose steroids (10 mg/day or more of prednisone or equivalent).
- Have a history of cancer affecting the brain or spinal cord, even if treated.
- Have certain types of blood cancers or conditions, such as plasma cell neoplasm, T-cell lymphoma, or specific types of B-cell lymphomas.
- Have a history of a slow-growing lymphoma that has changed into a more aggressive form, except for certain cases that are eligible for specific parts of the study.
Note: There may be other criteria that apply as defined by the study protocol.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.